Accessibility Menu
MDxHealth logo

MDxHealth(NASDAQ) MDXH

Market Cap$23.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2009)-99%
5 Year-97%
1 Year-83%
1 Month-5%
$0.46
-0.43%
-0.00Today
MDxHealth last closing stock price
MetricPriceDate
Last closeUSD 0.452026-08-10
MDxHealth stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.22%USD 0.462026-08-03
1 month-4.62%USD 0.482026-07-10
3 month-75.72%USD 1.872026-05-12
Year to date-87.28%USD 3.572025-12-31
1 year-82.93%USD 2.662025-08-08
3 year-87.03%USD 3.502023-07-14
5 year-96.93%USD 14.802021-08-11
Since inception-99.47%USD 87.502009-06-15

MDxHealth Financials at a Glance

Market Cap

$23.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$171.32M

Net Income (TTM)

-$64.22M

EPS (TTM)

-$0.66

P/E Ratio

-0.70

Dividend

$0.00

Beta (Volatility)

13465.45 (High)

Price

$0.46

Volume

175,369.603

Open

$0.48

Previous Close

$0.45

Daily Range

$0.45 - $0.48

52-Week Range

$0.40 - $5.33

Estimated Earnings Date

Aug 13, 2026

MDXH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MDxHealth

MDxHealth S.A. is a commercial-stage precision diagnostics firm specializing in urologic solutions globally. The company offers innovative genomic testing for prostate cancer, significantly enhancing diagnostic accuracy while reducing the need for invasive procedures.

Products and Services
  • SelectMDx: A non-invasive urine test for prostate cancer detection
  • ConfirmMDx: An epigenetic diagnostic tool for confirming prostate cancer
  • Comprehensive support services for healthcare professionals and patients
Growth Outlook
  • Recent quarterly revenue reached $54.7 million, indicating strong market demand
  • Expansion into new European markets is underway, enhancing growth potential
  • Continued investment in R&D aims to innovate and diversify product offerings
Financial Highlights
  • Trailing twelve months revenue of $146.5 million reflects a solid growth trajectory
  • Gross profit margin improved to 57.7%, showcasing operational efficiency
  • Cash reserves of $29 million provide a buffer for ongoing operations
MDxHealth S.A. operates in the medical diagnostics and research sector, focusing on precision medicine. The company's flagship products, SelectMDx and ConfirmMDx, are designed to improve the detection and management of prostate cancer, a significant health concern worldwide. With a strong international presence, including the United States and various European countries, MDxHealth is well-positioned to capitalize on the growing demand for advanced diagnostic solutions. The growth outlook for MDxHealth is promising, driven by recent revenue increases and strategic market expansions. The company is actively investing in research and development to enhance its product portfolio, which may lead to further revenue growth and market penetration. Financially, MDxHealth has demonstrated resilience, with a notable gross profit margin and sufficient cash reserves to support its operations and growth initiatives. Overall, MDxHealth S.A. presents a compelling opportunity for investors interested in the healthcare sector, particularly in the rapidly evolving field of precision diagnostics.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

364

CEO

Michael K. McGarrity

Website

www.mdxhealth.com

Headquarters

Herstal, WA 4040, BE

MDXH Financials

Key Financial Metrics (TTM)

Gross Margin

57.68%

Operating Margin

-16.59%

Net Income Margin

-32.17%

Return on Equity

402.97%

Return on Capital

-18.55%

Return on Assets

-17.67%

Earnings Yield

-1.43%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

51.36M

Volume

175.37K

Avg. Volume

827.84K

Financials (TTM)

Gross Profit

$102.02M

Operating Income

-$38.21M

EBITDA

-$21.09M

Operating Cash Flow

-$19.75M

Capital Expenditure

-$2.58M

Free Cash Flow

-$22.33M

Cash & ST Invst.

$29.03M

Total Debt

$95.11M

MDxHealth Performance Analysis

MDxHealth annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 37,054,00066.6%
20232023-12-31USD 70,193,00089.4%
20242024-12-31USD 90,049,00028.3%
20252025-12-31USD 107,875,00019.8%
MDxHealth sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-308.4%
Q42024-12-3114.4%
Q22025-06-30-44.6%
Q42025-12-31105.5%
MDxHealth annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.7816.7%
20232023-12-31USD -1.66-40.1%
20242024-12-31USD -1.16-30.4%
20252025-12-31USD -0.67-42.1%
MDxHealth sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-303.9%
Q42024-12-3147.9%
Q22025-06-3021.1%
Q42025-12-31-23.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$54.67M

+41.1%

Gross Profit

$29.31M

+16.2%

Gross Margin

53.61%

N/A

Market Cap

$23.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$65.05K

N/A

Employees

364

N/A

Net Income

-$18.78M

+9.6%

EBITDA

-$6.74M

+60.5%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$29.03M

+29.7%

Total Debt

$95.11M

+130.5%

Accounts Receivable

$14.68M

+30.2%

Inventory

$6.74M

+142.6%

Long Term Debt

$93.22M

+138.1%

Short Term Debt

$1.90M

-10.6%

Return on Assets

-17.67%

N/A

Return on Invested Capital

-13.70%

N/A

Free Cash Flow

$324.00K

+102.4%

Operating Cash Flow

$378.00K

+103.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNWVSANUWAVE Health Inc.
$5.73-2.55%
QTRXQuanterix Corporation
$2.42-39.95%
XGNExagen Inc.
$6.64-3.35%
IMRXImmuneering Corporation
$4.53+0.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About MDXH

What is the current price of MDxHealth?

MDxHealth is trading at $0.45 per share.

What is the 52-week range for MDxHealth?

Over the past 52 weeks, MDxHealth has traded between $0.40 and $5.33.

How much debt does MDxHealth have?

As of the most recent reporting period, MDxHealth reported total debt of $105.88M.

How much cash does MDxHealth have on hand?

MDxHealth reported $43.15M in cash and cash equivalents in its most recent financial results.

What is MDxHealth’s dividend yield?

MDxHealth does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services